Cited by 118Cervical Cancer and HPV ResearchGenital Health and DiseaseVaccine Coverage and Hesitancy

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials

Open access

Whitworth, Hilary S., Gallagher, Katherine E., Howard, Natasha, Mounier-Jack, Sandra, Mbwanji, Gladys, Kreimer, Aimée R., Basu, Partha, Kelly, Helen, Drolet, Mélanie, Brisson, Marc, Watson-Jones, Deborah·2020·Vaccine

DOI 10.1016/j.vaccine.2019.12.017

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVES: This study aimed to systematically review the literature on the efficacy and immunogenicity of single-dose HPV vaccination compared to no vaccination or multi-dose schedules among vaccine trial participants. METHODS: Medline, EMBASE, Global Health Database and Cochrane Central Register of Controlled Trials were searched for publications and conference abstracts (dated January 1999-August 2018) using MeSH and non-MeSH terms for human papillomavirus AND vaccines AND (immunogenicity OR efficacy/effectiveness) AND dosage. Search results were screened against pre-specified eligibility criteria. Data were extracted from included articles, and a narrative synthesis conducted on efficacy against HPV16/18 infection and humoral immunogenicity. RESULTS: Seven of 6,523 unique records identified were included in the review. Six were nested observational studies of participants randomised to receive two or three doses in three large HPV vaccine trials, in which some participants did not complete their allocated schedules. One small pilot study prospectively allocated participants to receive one or no vaccine dose. Frequency of HPV16/18 infection was low (e.g. <1% for 12-month-persistent infection) in all vaccinated participants up to seven years post vaccination and did not significantly differ by number of doses (p > 0.05 in all cases). Frequency of infection was significantly lower in one-dose recipients compared to unvaccinated controls (p < 0.01 for all infection endpoints in each study). HPV16/18 seropositivity rates were high in all HPV vaccine recipients (100% in three of four studies reporting this endpoint), though antibody levels were lower with one compared to two or three doses. CONCLUSIONS: This review supports the premise that one HPV vaccine dose may be as effective in preventing HPV infection as multi-dose schedules in healthy young women. However, it also highlights the paucity of available evidence from purpose-designed, prospectively-randomised trials. Results from ongoing clinical trials assessing the efficacy and immunogenicity of single-dose HPV vaccination compared to currently-recommended schedules are awaited.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2019.12.017

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Global Burden of Human Papillomavirus and Related Diseases
Forman, D., de Martel, C., Lacey, C. J., Soerjomataram, I., Lortet‐Tieulent, J., Bruni, L., Vignat, J., Ferlay, J., Bray, F., Plummer, M., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.07.055 · Cited by 1,685
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women
Paavonen, J., Naud, P., Salmerón, J., Wheeler, C., Chow, S.-N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J., Skinner, Sr., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61248-4 · Cited by 1,655
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
A review of clinical trials of human papillomavirus prophylactic vaccines
Schiller, J. T., Castellsagué, X., & Garland, S. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.108 · Cited by 747
Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study
Simms, K. T., Steinberg, J., Caruana, M., Smith, M. A., Lew, J.-B., Soerjomataram, I., Castle, P. E., Bray, F., & Canfell, K. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30836-2 · Cited by 486
The projected timeframe until cervical cancer elimination in Australia: a modelling study
Hall, M. T., Simms, K. T., Lew, J., Smith, M. A., Brotherton, J. M. L., Saville, M., Frazer, I. H., & Canfell, K. (2018) · The Lancet Public Health · doi:10.1016/s2468-2667(18)30183-x · Cited by 448
Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
Kreimer, A. R., Rodríguez, A. C., Hildesheim, A., Herrero, R., Porras, C., SCHIFFMAN, M. H., González, P., Solomon, D., Jiménez, S., Schiller, J. T., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr319 · Cited by 324
Self-citation
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
Kreimer, A. R., Struyf, F., Rosario‐Raymundo, M. R. D., Hildesheim, A., Skinner, S. R., Wacholder, S., Garland, S. M., Herrero, R., David, M., & Wheeler, C. M. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00047-9 · Cited by 316
Self-citation
Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models
Brisson, M., Bénard, É., Drolet, M., Bogaards, J. A., Baussano, I., Vänskä, S., Jit, M., Boily, M.-C., Smith, M. A., Berkhof, J., et al. (2016) · The Lancet Public Health · doi:10.1016/s2468-2667(16)30001-9 · Cited by 307
Self-citation

Show all 34 references

Research works printed but not linked: 2

WHO. Human papillomavirus vaccines: WHO position paper, October 2014. Weekly Epidemiological Record. 2014;89(43):465–92.
Deeks JJ, Higgins JP. Statistical algorithms in review manager 5. Statistical Methods Group of The Cochrane Collaboration; 2010. p. 1–11.

Sorted by citations

Cancer of the cervix uteri: 2021 update
Bhatla, N., Aoki, D., Sharma, D. N., & Sankaranarayanan, R. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13865 · Cited by 644
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study
Basu, P., Malvi, S. G., Joshi, S., Bhatla, N., Muwonge, R., Lucas, E., Verma, Y., Esmy, P. O., Poli, U. R. R., Shah, A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00453-8 · Cited by 272
Self-citation
Human papillomavirus vaccination and cervical cancer risk
Rahangdale, L., Mungo, C., O’Connor, S., Chibwesha, C. J., & Brewer, N. T. (2022) · BMJ · doi:10.1136/bmj-2022-070115 · Cited by 228
Cervical cancer prevention and control in women living with human immunodeficiency virus
Castle, P. E., Einstein, M. H., & Sahasrabuddhe, V. V. (2021) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21696 · Cited by 224
Vaccine delivery systems toward lymph nodes
Ding, Y., Li, Z., Jaklenec, A., & Hu, Q. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113914 · Cited by 191
National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects
Tsu, V. D., LaMontagne, D. S., Atuhebwe, P. L., Bloem, P. N., & Ndiaye, C. (2021) · Preventive Medicine · doi:10.1016/j.ypmed.2020.106335 · Cited by 174
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Zhou, Y., Xie, Y., Tang, L., Pu, D., Zhu, Y., Liu, J., & Ma, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00733-x · Cited by 116
Immunogenicity and Safety Results Comparing Single Dose Human Papillomavirus Vaccine with Two or Three Doses in Tanzanian Girls - the DoRIS Randomised Trial
Watson‐Jones, D., Changalucha, J. M., Whitworth, H. S., Pinto, L. A., Mutani, P., Indangasi, J., Kemp, T. J., Hashim, R., Kamala, B., Wiggins, R. C., et al. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00309-6 · Cited by 120
Self-citation
Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results
Barnabas, R. V., Brown, E. R., Onono, M. A., Bukusi, E. A., Njoroge, B., Winer, R. L., Galloway, D. A., Pinder, L. F., Donnell, D. J., Wakhungu, I., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02658-0 · Cited by 104
A Framework for Cervical Cancer Elimination in Low-and-Middle-Income Countries: A Scoping Review and Roadmap for Interventions and Research Priorities
Shin, M., Liu, G., Mugo, N., Garcia, P. J., Rao, D. W., Broshkevitch, C. J., Eckert, L. O., Pinder, L. F., Wasserheit, J. N., & Barnabas, R. V. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.670032 · Cited by 81
Advances in the polymeric delivery of nucleic acid vaccines
Chen, G., Zhao, B., Ruiz, E. F., & Zhang, F. (2022) · Theranostics · doi:10.7150/thno.70853 · Cited by 76
Human papillomavirus vaccination in the European Union/European Economic Area and globally: a moral dilemma
Colzani, E., Johansen, K., Johnson, H., & Pastore Celentano, L. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.50.2001659 · Cited by 86
Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis
Prem, K., Choi, Y. H., Bénard, É., Burger, E. A., Hadley, L., Laprise, J., Regan, M. C., Drolet, M., Sy, S., Abbas, K., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02988-3 · Cited by 78
Self-citation
Cancer Prevention in Low-Resource Countries: An Overview of the Opportunity
Kamaraju, S., Drope, J. M., Sankaranarayanan, R., & Shastri, S. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280625 · Cited by 60
Public health concern-driven insights and response of low- and middle-income nations to the World health Organization call for cervical cancer risk eradication
Reza, S., Anjum, R., Khandoker, R. Z., Khan, S. R., Islam, M. R., & Dewan, S. M. R. (2024) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2024.101460 · Cited by 54
The clinical effectiveness of one-dose vaccination with an HPV vaccine: A meta-analysis of 902,368 vaccinated women
Setiawan, D., Nurulita, N. A., Khoirunnisa, S. M., & Postma, M. J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0290808 · Cited by 45
Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study
Man, I., Georges, D., de Carvalho, T. M., Ray Saraswati, L., Bhandari, P., Kataria, I., Siddiqui, M., Muwonge, R., Lucas, E., Berkhof, J., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00543-5 · Cited by 44
Self-citation
Human malignancies associated with persistent HPV infection
McBride, A. A. (2024) · The Oncologist · doi:10.1093/oncolo/oyae071 · Cited by 50
Cervical cancer trends, HPV vaccine utilization, and screening in low- and lower-middle-income countries: an updated review
Hamid, M. K. I., Hasneen, S., Lima, A. K., Shawon, S. R., Shahriar, M., & Anjum, R. (2025) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355251356646 · Cited by 41
HPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial
Porras, C., Romero, B., Kemp, T. J., Fantin, R., Herrero, R., Hildesheim, A., Ocampo, R., Sierra, M. S., Gail, M. H., Schussler, J. E., et al. (2024) · JNCI Monographs · doi:10.1093/jncimonographs/lgae032 · Cited by 32
Self-citation
Communication strategies to improve human papillomavirus (HPV) immunisation uptake among adolescents in sub-Saharan Africa: a systematic review and meta-analysis
Oketch, S. Y., Ochomo, E. O., Orwa, J., Mayieka, L., & Abdullahi, L. H. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-067164 · Cited by 39
HPV Vaccination: The Position Paper of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV)
Ciavattini, A., Giannella, L., Vincenzo, R. D., Giuseppe, J. D., Papiccio, M., Lukic, A., Carpini, G. D., Perino, A., Frega, A., Sopracordevole, F., et al. (2020) · Vaccines · doi:10.3390/vaccines8030354 · Cited by 29
A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG
Dijkman, K., Lindenstrøm, T., Rosenkrands, I., Søe, R., Woodworth, J. S., Arlehamn, C. S. L., & Mortensen, R. J. (2023) · npj Vaccines · doi:10.1038/s41541-023-00666-2 · Cited by 27
Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials
Whitworth, H. S., Mounier‐Jack, S., Choi, E. M.-L., Gallagher, K. E., Howard, N., Kelly, H. A., Mbwanji, G., Kreimer, A. R., Basu, P. S., Barnabas, R. V., et al. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100486 · Cited by 23
Self-citation
Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania
Hsiao, A., Struckmann, V., Stephani, V., Mmbando, D., Changalucha, J. M., Baisley, K. J., Levin, A., Morgan, W., Hutubessy, R. C. W., Watson‐Jones, D., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.11.032 · Cited by 22
Self-citation
Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom
Daniels, V., Saxena, K., Patterson‐Lomba, O., Gómez-Liévano, A., Saah, A. J., Luxembourg, A. T., Velicer, C. M., Chen, Y., & Elbasha, E. H. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.067 · Cited by 23
Acting on the call: A framework for action for rapid acceleration of access to the HPV vaccination in low‐ and lower‐middle‐income countries
Kumar, S., Khanduri, A., Sidibe, A., Morgan, C., Torode, J., Basu, P. S., Bhatla, N., Schocken, C., & Bloem, P. N. (2020) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13482 · Cited by 20
Self-citation
An Update on Human Papillomavirus Vaccination in the United States
Boitano, T. K. L., Ketch, P. W., Scarinci, I. C., & Huh, W. K. (2023) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005056 · Cited by 19
The efficacy of vaccination to prevent human papilloma viruses infection at anal and oral: a systematic review and meta-analysis
Zhang, J., Qin, Z., Lou, C., Huang, J., & Xiong, Y. (2021) · Public Health · doi:10.1016/j.puhe.2021.05.012 · Cited by 19
Preventing Cervical Cancer Globally: Are We Making Progress?
Allanson, E. R., & Schmeler, K. M. (2021) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-21-0016 · Cited by 18
Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer
Ding, H., Zhang, J., Zhang, F., Xu, Y., Yu, Y., Liang, W., & Li, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.990877 · Cited by 17
Evaluations of water, sanitation and hygiene interventions should not use diarrhoea as (primary) outcome
Watson, S., Rego, R. T. T., Hofer, T. P., & Lilford, R. J. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2022-008521 · Cited by 19
HPV16/18 Antibody Responses After a Single Dose of Nonavalent HPV Vaccine
Zeng, Y., Moscicki, A., Woo, H., Hsu, C., Kemp, T. J., Pinto, L. A., Szabo, E. M., Dimond, E. P., Bauman, J. E., Sahasrabuddhe, V. V., et al. (2023) · PEDIATRICS · doi:10.1542/peds.2022-060301 · Cited by 16
Annual immunisation coverage report 2021 - 14 October 2022
Hull, B. P., Hendry, A., Dey, A., Brotherton, J. M. L., Macartney, K. K., & Beard, F. (2023) · Communicable Diseases Intelligence · doi:10.33321/cdi.2023.47.47 · Cited by 16
Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9–14-year-old and 18–26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial
Li, J., Shi, L.-W., Li, K., Huang, L., Li, J.-B., Dong, Y.-L., Li, W., Ji, M., Yang, Q. K., Zhou, L., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.041 · Cited by 16
If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment?
Tjalma, W. A. A., van Heerden, J., & WYNGAERT, T. V. D. (2021) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2021.11.008 · Cited by 16
Strong reduction in prevalence of HPV16/18 and closely related HPV types in sexually active adolescent women following the introduction of HPV vaccination in Argentina
González, J. V., Deluca, G., Correa, R. M., Liotta, D. J., Basiletti, J. A., Fellner, M. D., Colucci, M. C., Alzogaray, O. G., Katz, N., Carmona, J. J., et al. (2020) · Papillomavirus Research · doi:10.1016/j.pvr.2020.100208 · Cited by 15
Nationwide introduction of HPV vaccine in Zimbabwe 2018–2019: Experiences with multiple cohort vaccination delivery
Carlton, J. G., Marembo, J., Manangazira, P., Rupfutse, M., Shearley, A., Makwabarara, E., Hidle, A., & Loharikar, A. R. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000101 · Cited by 14
The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss
Lalonde, C. S., Teng, Y., Burtness, B. A., Ferris, R. L., Ahmed, R., & Saba, N. F. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac098 · Cited by 14
Efficacy and Durability of Immune Response after Receipt of HPV Vaccines in People Living with HIV
Losada, C., Samaha, H., Scherer, E. M., Kazzi, B., Khalil, L. E., Ofotokun, I., & Rouphael, N. (2023) · Vaccines · doi:10.3390/vaccines11061067 · Cited by 14
Human papillomavirus infection and seroprevalence among female university students in Mexico
Pedroza‐González, A., Reyes‐Reali, J., Campos-Solorzano, M., Blancas-Diaz, E. M., Tomás-Morales, J. A., Hernandez-Aparicio, A. A., de Oca‐Samperio, D. M., Garrido, E., García-Romo, G. S., Méndez-Catalá, C. F., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2028514 · Cited by 14
Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysisPreprint
Prem, K., Choi, Y. H., Bénard, É., Burger, E. A., Hadley, L., Laprise, J., Regan, M. C., Drolet, M., Sy, S., Abbas, K., et al. (2021) · medRxiv · doi:10.1101/2021.02.08.21251186 · Cited by 13
Self-citation
Human papillomavirus vaccine uptake and its determinants among women in Africa: an umbrella review
Mengistie, B. A., Yirsaw, A. N., Lakew, G., Mekonnen, G. B., Shibabaw, A. A., Chereka, A. A., Kitil, G. W., Wondie, W. T., Abuhay, A. E., & Getachew, E. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1537250 · Cited by 12
Prevención de las enfermedades infecciosas. Actualización en vacunas PAPPS 2022
Martín, S. M., Agustí, M. L. M., Miranda, A. P. J., Hernández, C. S., Chavarri, G. S., Herce, P. A., García-Iglesias, C., Marco, J. J. G., & Pérez, M. I. G. (2022) · Atención Primaria · doi:10.1016/j.aprim.2022.102462 · Cited by 11
Effective vaccination strategies for human papillomavirus (HPV) infection and cervical cancer based on the mathematical model with a stochastic process
Kim, M., & Kim, E. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29558 · Cited by 10
HPV Vaccines – An Overview
Ghosh, A., Chatterjee, S., Dawn, A., & Das, A. (2025) · Indian Journal of Dermatology · doi:10.4103/ijd.ijd_805_24 · Cited by 12
HPV vaccination coverage: slightly improved two‐dose schedule completion estimates and historical estimates lower on AIR than HPV Register
Brotherton, J. M. L., Hendry, A., Dey, A., Hull, B. P., & Beard, F. (2022) · Australian and New Zealand Journal of Public Health · doi:10.1111/1753-6405.13233 · Cited by 10
Respiratory Syncytial Virus (RSV) Disease and Prevention Products: Knowledge, Attitudes, and Preferences of Kenyan Healthcare Workers in Two Counties in 2021
Nyawanda, B. O., Opere, V. A., Nyiro, J. U., Vodicka, E. L., Fleming, J. A., Baral, R., Khan, S., Pecenka, C. J., Ayugi, J., Atito, R., et al. (2023) · Vaccines · doi:10.3390/vaccines11061055 · Cited by 9
HPV vaccination leads to decrease of anogenital warts and precancerous lesions of the cervix uteri in young women with low vaccination rates: a retrospective cohort analysis
Osmani, V., Fett, S., Tauscher, M., Donnachie, E., Schneider, A., & Klug, S. J. (2022) · BMC Cancer · doi:10.1186/s12885-022-10214-1 · Cited by 9
Prevalence of Oral Human Papillomavirus Infection by Number of Vaccine Doses Among US Adults
Abel, M. K., Mann, A. K., Sonawane, K., Kapp, D. S., Deshmukh, A. A., & Chan, J. K. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab086 · Cited by 9
HPV Infection in Children and Adolescents—A Comprehensive Review
Tomecka, P., Karwowska, A., Kuźnicki, J., Skinderowicz, K., Wojno, A., Markut, K., Typek, P., Ciesielska, U., Kulbacka, J., & Drąg‐Zalesińska, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072425 · Cited by 8
Enhancing equity in cervical screening – initiatives to increase screening participation
Costa, T., Bateson, D. J., & Woo, Y. L. (2024) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000979 · Cited by 8
Prävention HPV-induzierter Erkrankungen durch prophylaktische Impfung
Wieland, U., & Kreuter, A. (2020) · Der Hautarzt · doi:10.1007/s00105-020-04739-4 · Cited by 9
Adolescent Health Series: HPV infection and vaccination in sub‐Saharan Africa: 10 years of research in Tanzanian female adolescents ‐ narrative review
Whitworth, H. S., Changalucha, J. M., Baisley, K. J., & Watson‐Jones, D. (2021) · Tropical Medicine & International Health · doi:10.1111/tmi.13660 · Cited by 10
Self-citation
The one-dose schedule opens the door to rapid scale-up of HPV vaccination
Zou, Z., & Zhang, L. (2023) · BMC Medicine · doi:10.1186/s12916-023-03097-x · Cited by 8
Transforming drug and vaccine delivery for equitable access in global health
Yang, X., Zhang, L., Staykov, K., Wu, Z., & Jaklenec, A. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152415 · Cited by 7
Leveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings
Man, I., Georges, D., Basu, P. S., & Baussano, I. (2024) · JNCI Monographs · doi:10.1093/jncimonographs/lgae035 · Cited by 7
Self-citation
Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination program in adolescents in low/middle-income countries: An analysis of Indonesia
Daniels, V., Saxena, K., Patterson‐Lomba, O., Gómez-Liévano, A., Thobari, J. A., Durand, N., & Myers, E. R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310591 · Cited by 6
Modeling the Health Impact and Cost-Effectiveness of a Combined Schoolgirl HPV Vaccination and Cervical Cancer Screening Program in Guangdong Province, China
Huang, Y., Zhang, D., Yin, L., Zhao, J., Li, Z., Lu, J., Zhang, X., Wu, C., & Wu, W. (2024) · Children · doi:10.3390/children11010103 · Cited by 6
A literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvements
Pluijmaekers, A. J. M., Steens, A., Houweling, H., Rots, N. Y., Benschop, K., van Binnendijk, R. S., Bodewes, R., Brouwer, J. G. M., Buisman, A., Duizer, E., et al. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100556 · Cited by 6
A novel C-terminal modification method enhanced the yield of human papillomavirus L1 or chimeric L1-L2 virus-like particles in the baculovirus system
Ma, M., Xia, B., Wang, Z., Hao, Y., Zhang, T., & Xu, X. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1073892 · Cited by 6
Human Papillomavirus Vaccines
Schiller, J. T., Markowitz, L. E., Kreimer, A. R., & Lowy, D. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00032-3 · Cited by 6
Self-citation
Acceptability of single-dose HPV vaccination schedule among health-care professionals in Kenya: a mixed-methods study
Umutesi, G., Weiner, B. J., Oluoch, L. M., Bukusi, E. A., Onono, M. A., Njoroge, B. W., Mecca, L., Ngure, K., Mugo, N., & Barnabas, R. V. (2024) · JNCI Monographs · doi:10.1093/jncimonographs/lgae031 · Cited by 5
Recommendations and guidance for human papillomavirus (HPV) vaccination for adults in Taiwan
Lin, K., Lin, I.-F., Wu, P.-F., Tsai, W.-C., Su, L.-Y., Chang, C.-N., Huang, W.-H., Wang, C.-H., Hung, M.-C., Huang, C.-H., et al. (2025) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2025.03.009 · Cited by 5
The Clinical Effectiveness of Single-Dose Human Papillomavirus Vaccination
Bao, W., He, X., Huang, Y., Liu, R., & Li, Z. (2024) · Vaccines · doi:10.3390/vaccines12090956 · Cited by 5
Prospects for Comprehensive Screening and Treatment of Cervical Cancer
Begliarzade, S., Mukhametova, R. R., & Zhao, B. (2024) · Creative Surgery and Oncology · doi:10.24060/2076-3093-2024-14-1-60-68 · Cited by 6
Key ethical considerations to guide the adjudication of a single-dose HPV vaccine schedule
Shadab, R., Lavery, J. V., McFadden, S. M., Elharake, J. A., Malik, F. A., & Omer, S. B. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1917231 · Cited by 5
Parental Knowledge and Acceptance of HPV Vaccine in Rabigh’s School, Saudi Arabia
Alghanmi, R., Alkhalawi, E., Albeladi, R. S., Albeladi, S. M., Alghamdi, M., Fayoumi, A., & Nassif, R. A. (2026) · Annals of Global Health · doi:10.5334/aogh.4866 · Cited by 4
Human papillomavirus vaccination coverage among young women in the three sub-Saharan African countries using Demographic and Health Surveys data
Wassie, M., Zegeye, A. F., Mekonen, E. G., Tekeba, B., Ali, M. S., Gonete, A. T., Kassie, A. T., Workneh, B. S., Alemu, T. G., & Tamir, T. T. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2370111 · Cited by 4
Exploring the complexity of the implementation determinants of human papillomavirus vaccination in Africa through a systems thinking lens: A rapid review
Adamu, A. A., Jalo, R. I., Ndwandwe, D. E., & Wiysonge, C. S. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2381922 · Cited by 4
Immunogenicity and duration of antibodies after vaccination with a two-dose series of the nine-valent human papillomavirus vaccine among Alaska Native children: a prospective cohort study
Steinberg, J., Panicker, G., Unger, E. R., Blake, I., Lewis, R. M., Geis, J., Bruden, D. J. T., Fischer, M., Markowitz, L. E., & Bruce, M. G. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10961-z · Cited by 3
Knowledge and acceptability of male HPV vaccination among young people and community stakeholders in northwest Tanzania: social sciences in the Add-Vacc trial
Kelly, S., Changalucha, J. M., Malibwa, D., Ewing, V., Mkungu, G., Deogratias, D., Hashim, R., Stanley, M., Lacey, C., Hayes, R., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.128002 · Cited by 3
Self-citation
A single-injection vaccine providing protection against two HPV types
Zhang, J., Liu, Y., Guan, Y., & Zhang, Y. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00606b · Cited by 3
Human papillomavirus vaccine guideline adherence among Arizona’s Medicaid beneficiaries
Koskan, A. M., Klasko-Foster, L. B., Stecher, C. D., Rodríguez, S. A., Helitzer, D., & Yoo, W. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.12.041 · Cited by 3
La vaccinazione anti-papillomavirus: mai più senza!
Russo, R., & Marchetti, F. (2024) · Medico e Bambino · doi:10.53126/meb43575 · Cited by 3
Influences on male college students’ patient-provider communications and uptake behaviors related to the human papillomavirus vaccine
Koskan, A. M., Stecher, C. D., & Helitzer, D. (2022) · Journal of American College Health · doi:10.1080/07448481.2022.2086004 · Cited by 3
Different dose series of human papillomavirus vaccine in young females: a pair-wise meta-analysis and network meta-analysis from randomized controlled trials
Li, K., Mengpei, Z., Zeng, J., & Rutie, Y. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1152057 · Cited by 2
Evaluation of HPV-loaded PLGA microparticles as single-dose HPV vaccine: Insights for sustained-release vaccine development
Zhang, Y., Sullivan, N., Abraham, M., Haley, H., Liu, Y., Mahan, E., Hines, C. D. G., Tomaszewski, M. R., Miller, C. O., Bakthavatchalu, V., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127024 · Cited by 3
Immune response after one dose of HPV vaccine among girls and boys and the impact of a second dose given after 3 or more years
Guzun, N., Ouakki, M., Panicker, G., Ionescu, I. G., Mayrand, M., Unger, E. R., & Sauvageau, C. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127475 · Cited by 2
Vaccination against human papillomavirus is a fundamental factor in the prevention of cervical cancer (review)
Enkova, E. V., Kiseleva, Е. V., Khoperskaya, O. V., Вячеславович, Ш. С., Dukhanina, E. S., & Sentsova, E. Y. (2021) · RESEARCH RESULTS IN BIOMEDICINE · doi:10.18413/2658-6533-2021-7-2-0-9 · Cited by 2
As barreiras das mulheres que fazem sexo com mulheres no acesso à saúde no Brasil
de Araújo, R. A. S., Oliveira, R. D. S., Dias, J. M. G., Fontes, G. D. Q., Silva, T. S. L. D. B., Gonçalves, A. S. S., & Albuquerque, A. A. (2021) · Research Society and Development · doi:10.33448/rsd-v10i17.23602 · Cited by 2
The Clinical Effectiveness of One-Dose HPV Vaccine: A meta-analysis of 902,368 vaccinated womenPreprint
Setiawan, D., Nurulita, N. A., Khoirunnisa, S. M., & Postma, M. J. (2023) · medRxiv · doi:10.1101/2023.08.17.23294214 · Cited by 2
Decoding impact of human papillomavirus in gynecological oncology: a narrative review
Sarker, M. S., & Pervez, M. M. (2025) · Obstetrics & Gynecology Science · doi:10.5468/ogs.24226 · Cited by 1
Human papillomavirus vaccination uptake among men who have sex with men living with HIV
Moran, C., García-Iglesias, J., & Kerr, C. (2025) · Sexually Transmitted Infections · doi:10.1136/sextrans-2024-056361 · Cited by 1
Long term immunogenicity of two doses of the quadrivalent HPV vaccine and the effect of an additional dose given five years post-primary vaccination
Sauvageau, C., Ionescu, I. G., Ouakki, M., Panicker, G., Unger, E. R., Gîlca, V., & Mayrand, M. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127893 · Cited by 1
Long-term effectiveness of at least one dose of human papillomavirus vaccine in adolescents: A test-negative case–control study
Kamolratanakul, S., Niyom, S. L., Ayudaya, N. I. N., Ruengprasertkit, C., Horthongkham, N., Sripradit, K., Dhitavat, J., Muangnoicharoen, S., Sunthornchart, S., & Pitisuttithum, P. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.108489 · Cited by 1
Immunogenicity and Safety of One-Dose Human Papillomavirus Vaccine Compared With Two or Three Doses in Tanzanian Girls (DoRIS): An Open-Label, Randomised, Non-inferiority Trial
Watson‐Jones, D., Changalucha, J. M., Whitworth, H. S., Pinto, L. A., Mutani, P., Indangasi, J., Kemp, T. J., Hashim, R., Kamala, B., Wiggins, R. C., et al. (2023) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001135 · Cited by 1
Self-citation
Human papillomavirus vaccine
Rajaram, S., Sahoo, I., Heda, A., & SINGH, L. (2023) · Current Medicine Research and Practice · doi:10.4103/cmrp.cmrp_28_23 · Cited by 1
Quince años de vacunación frente al virus del papiloma humano en España. Actualización
Llop, F. A. M. (2023) · Vacunas · doi:10.1016/j.vacun.2023.05.001 · Cited by 2
Epigenetic Factor MicroRNAs Likely Mediate Vaccine Protection Efficacy against Lymphomas in Response to Tumor Virus Infection in Chickens through Target Gene Involved Signaling Pathways
Zhang, L., Xie, Q., Chang, S., Ai, Y., Dong, K., & Zhang, H. (2024) · Veterinary Sciences · doi:10.3390/vetsci11040139 · Cited by 1
Surveillance of High-Risk Type-16 and 18 Human Papillomavirus among HIV Positive and Non-Positive Individuals at Federal Teaching Hospital Ebonyi State Nigeria
Onu, E. N., Ilang, D. C., Azi, C. I., Eze, T. O., Akpa, C. O., Ogbonna, O. E., Agada, S. E., & Onwe, M. C. (2024) · Advances in Microbiology · doi:10.4236/aim.2024.1412045 · Cited by 1
Should the cervical dysplasia (CIN2+) recurrence nomogram be used for HPV vaccination triage after conization?
Tjalma, W. A. A. (2020) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000584 · Cited by 2
Neues zu Impfungen bei Erwachsenen
Seybold, U. (2020) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0982-8894
Impfprävention HPV-assoziierter Neoplasien
Wieland, U., & Kreuter, A. (2022) · Forum · doi:10.1007/s12312-022-01063-x
Prävention HPV-induzierter Erkrankungen durch prophylaktische Impfung
Wieland, U., & Kreuter, A. (2022) · best practice onkologie · doi:10.1007/s11654-022-00372-w
Implementation of HPV vaccine worldwide and in Japan
Fujii, T. (2022) · 日本臨床細胞学会雑誌 · doi:10.5795/jjscc.61.227
Fifteen years of vaccination against the human papilloma virus in Spain. An update
Llop, F. A. M. (2023) · Vacunas (English Edition) · doi:10.1016/j.vacune.2023.10.001
Impacto da pandemia COVID-19 no rastreamento organizado de câncer de colo uterino com teste de DNA-HPV em Indaiatuba-SP
Polegatto, I. (2022) · doi:10.47749/t/unicamp.2022.1259071
The Impact of Human Immunodeficiency Virus on Women in the United States
Guillaume, D. (2024) · Nursing Clinics of North America · doi:10.1016/j.cnur.2024.01.003
The second generation of domestic HPV vaccine based on Escherichia coli expression system can induce high titer neutralizing antibodies
Zhu, K., Bi, Z., Chen, Q., Zhong, G., Wu, T., Zhang, J., & Xia, N. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0880

Authors: Whitworth, H. S., Gallagher, K. E., Howard, N., Mounier-Jack, S., Mbwanji, G., Kreimer, A. R., Basu, P., Kelly, H., Drolet, M., Brisson, M., & Watson-Jones, D.
Affiliations: London School of Hygiene & Tropical Medicine (GB)
Mwanza Intervention Trials Unit (TZ)
National Institutes of Health (US)
Centre international de recherche sur le cancer (FR)
Centre de recherche du CHU de Québec-Université Laval (CA)
Université Laval (CA)
Corresponding author: Whitworth, Hilary S.
ORCID: Whitworth, Hilary S.
Gallagher, Katherine E.
Howard, Natasha
Mounier-Jack, Sandra
Mbwanji, Gladys
Kreimer, Aimée R.
Basu, Partha
Drolet, Mélanie
Brisson, Marc
Venue: Vaccine
Publisher: Elsevier BV
Published: 2020-02
Volume: 38
Issue: 6
Pages: 1302-1314
ISSN: 0264-410X (ISSN-L)
DOI: 10.1016/j.vaccine.2019.12.017
OpenAlex: W2995954663
Cited by: 118
References: 34
Citations by year: 2026: 9 · 2025: 20 · 2024: 25 · 2023: 20 · 2022: 19 · 2021: 17 · 2020: 8
FWCI: 1.60
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Vaccine (publishedVersion, cc-by)
PubMed (publishedVersion)
LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
National University of Singapore (submittedVersion)
Funders: PATH
Topics: Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
Health Sciences › Medicine › Surgery › Genital Health and Disease
Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords: HPV vaccine, single-dose vaccination, HPV16/18 infection, immunogenicity, vaccine efficacy, dosing regimen, seropositivity, antibody levels, HPV prevention, young women
MeSH terms: Immunogenicity, Vaccine, Female, Humans, Immunization Schedule, Vaccination, Randomized Controlled Trials as Topic, Papillomavirus Infections, Human papillomavirus 18, Human papillomavirus 16, Papillomavirus Vaccines, Immunity, Humoral, Observational Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks